These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17708574)

  • 21. In celebration of expectoration: induced sputum indices as outcome measures in cystic fibrosis.
    Armstrong DS
    Am J Respir Crit Care Med; 2003 Dec; 168(12):1412-3. PubMed ID: 14668253
    [No Abstract]   [Full Text] [Related]  

  • 22. BEATing cystic fibrosis: more on rhDNase and mild lung disease.
    Bush A
    Pediatr Pulmonol; 2004 Oct; 38(4):275-6. PubMed ID: 15334502
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series.
    Erdeve O; Uras N; Atasay B; Arsan S
    Croat Med J; 2007 Apr; 48(2):234-9. PubMed ID: 17436388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does the timing of inhaled dornase alfa matter?
    van der Giessen L
    J Cyst Fibros; 2009 Jun; 8 Suppl 1():S6-9. PubMed ID: 19460684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical benefit from nebulized human recombinant DNase in Kartagener's syndrome.
    Desai M; Weller PH; Spencer DA
    Pediatr Pulmonol; 1995 Nov; 20(5):307-8. PubMed ID: 8903903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Jet nebulising systems for recombinant human DNase I.
    Hung JC; Hambleton G; Super M
    Arch Dis Child; 1994 Dec; 71(6):558-9. PubMed ID: 7726622
    [No Abstract]   [Full Text] [Related]  

  • 27. Airway clearance therapy in cystic fibrosis patients.
    Pisi G; Chetta A
    Acta Biomed; 2009 Aug; 80(2):102-6. PubMed ID: 19848046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Restoring airway surface liquid in cystic fibrosis.
    Ratjen F
    N Engl J Med; 2006 Jan; 354(3):291-3. PubMed ID: 16421371
    [No Abstract]   [Full Text] [Related]  

  • 29. Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers.
    Cipolla D; Gonda I; Shire SJ
    Pharm Res; 1994 Apr; 11(4):491-8. PubMed ID: 8058603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. Pulmozyme Pediatric Broncoscopy Study Group.
    Wagener JS; Rock MJ; McCubbin MM; Hamilton SD; Johnson CA; Ahrens RC
    J Pediatr; 1998 Oct; 133(4):486-91. PubMed ID: 9787685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Airway clearance in cystic fibrosis.
    Goss CH
    Respir Care; 2003 Jan; 48(1):20-1. PubMed ID: 12556256
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
    Dopfer R; Brand P; Müllinger B; Hunger T; Häussermann S; Meyer T; Scheuch G; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):141-54. PubMed ID: 18204125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of mist tent therapy in cystic fibrosis using maximum expiratory flow volume curve.
    Motoyama EK; Gibson LE; Zigas CJ
    Pediatrics; 1972 Aug; 50(2):299-306. PubMed ID: 5045357
    [No Abstract]   [Full Text] [Related]  

  • 34. Formulation and process development of (recombinant human) deoxyribonuclease I as a powder for inhalation.
    Zijlstra GS; Ponsioen BJ; Hummel SA; Sanders N; Hinrichs WL; de Boer AH; Frijlink HW
    Pharm Dev Technol; 2009; 14(4):358-68. PubMed ID: 19552563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmaco-toxicological expert report Pulmozyme rhDNase Genentech, Inc.
    Green JD
    Hum Exp Toxicol; 1994 May; 13 Suppl 1():S1-42. PubMed ID: 8031609
    [No Abstract]   [Full Text] [Related]  

  • 36. Aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis.
    Rubin BK
    N Engl J Med; 1992 Aug; 327(8):571. PubMed ID: 1635583
    [No Abstract]   [Full Text] [Related]  

  • 37. Reversal of bronchial obstruction with bi-level positive airway pressure and nebulization in patients with acute asthma.
    Brandao DC; Lima VM; Filho VG; Silva TS; Campos TF; Dean E; de Andrade AD
    J Asthma; 2009 May; 46(4):356-61. PubMed ID: 19484669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature.
    Boogaard R; de Jongste JC; Merkus PJ
    Pediatr Pulmonol; 2007 Nov; 42(11):989-1001. PubMed ID: 17902149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypertonic saline for cystic fibrosis.
    Aziz I; Kastelik JA
    N Engl J Med; 2006 Apr; 354(17):1848-51; author reply 1848-51. PubMed ID: 16641405
    [No Abstract]   [Full Text] [Related]  

  • 40. Making airway clearance successful.
    Homnick DN
    Paediatr Respir Rev; 2007 Mar; 8(1):40-5. PubMed ID: 17419977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.